08:00 , Feb 13, 2012 |  BioCentury  |  Emerging Company Profile

Abide: Selecting serine hydrolases

Abide Therapeutics Inc. is developing an approach to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. Most of the new targets will require significant...
07:00 , May 5, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Arylacetamide deacetylase-like 1 (AADACL1; KIAA1363) An in vitro and mouse...